换一批
换一批
第一作者：
Yanzhao,Zhou
第一单位：
Laboratory of Cardiovascular Immunology, Key Laboratory of Molecular Targeted Therapies of the Ministry of Education, Institute of Cardiology, Union Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China *Yanzhao Zhou, Shijia Wang and Zhihua Qiu contributed equally to the writing of this article. †Yuhua Liao and Xiao Chen contributed equally to this study.
作者：
主题词
血管紧张素Ⅱ(Angiotensin II);血管紧张素Ⅱ1型受体拮抗剂(Angiotensin II Type 1 Receptor Blockers);动物(Animals);抗体, 中和(Antibodies, Neutralizing);主动脉(Aorta);载脂蛋白E类(Apolipoproteins E);细胞凋亡(Apoptosis);动脉粥样硬化(Atherosclerosis);趋化因子CCL2(Chemokine CCL2);冠状血管(Coronary Vessels);内皮细胞(Endothelial Cells);人类(Humans);巨噬细胞(Macrophages);男(雄)性(Male);小鼠(Mice);小鼠, 基因敲除(Mice, Knockout);斑块, 动脉粥样硬化(Plaque, Atherosclerotic);受体, 血管紧张素, 1型(Receptor, Angiotensin, Type 1);肾素-血管紧张素系统(Renin-Angiotensin System);清道夫受体, E类(Scavenger Receptors, Class E);疫苗(Vaccines);血管收缩药(Vasoconstrictor Agents)
DOI
10.1097/HJH.0000000000000835
PMID
26771341
发布时间
2018-12-02
- 浏览6
Journal of hypertension
474-85; discussion 485页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
